MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Raised to $66.00

MoonLake Immunotherapeutics (NASDAQ:MLTX) had its target price hoisted by Needham & Company LLC from $62.00 to $66.00 in a research note published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Thursday. Wedbush reissued an “outperform” rating and set a $73.00 target price (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. Finally, The Goldman Sachs Group raised MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $62.00 to $82.00 in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $83.20.

MoonLake Immunotherapeutics Trading Down 0.0 %

MLTX stock opened at $41.76 on Thursday. The company has a market capitalization of $2.67 billion, a PE ratio of -32.37 and a beta of 1.28. MoonLake Immunotherapeutics has a 12-month low of $37.55 and a 12-month high of $58.26. The business’s fifty day moving average price is $46.49 and its 200 day moving average price is $48.91.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.09). Research analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of MoonLake Immunotherapeutics during the 4th quarter worth about $1,091,000. Jefferies Financial Group Inc. acquired a new position in shares of MoonLake Immunotherapeutics during the 4th quarter worth about $338,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of MoonLake Immunotherapeutics by 17.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company’s stock worth $2,287,000 after acquiring an additional 6,422 shares in the last quarter. Woodline Partners LP boosted its position in shares of MoonLake Immunotherapeutics by 26.3% during the 4th quarter. Woodline Partners LP now owns 293,535 shares of the company’s stock worth $15,895,000 after acquiring an additional 61,105 shares in the last quarter. Finally, Wexford Capital LP boosted its position in shares of MoonLake Immunotherapeutics by 71.4% during the 4th quarter. Wexford Capital LP now owns 24,000 shares of the company’s stock worth $1,300,000 after acquiring an additional 10,000 shares in the last quarter. 93.85% of the stock is owned by institutional investors and hedge funds.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.